Resumen

CARRILLO-ESPER, Raúl et al. Alterations in coagulation in COVID-19. Cir. cir. [online]. 2020, vol.88, n.6, pp.787-793.  Epub 08-Nov-2021. ISSN 2444-054X.  https://doi.org/10.24875/ciru.20000416.

Infection with the SARS-CoV-2 virus and the development of all manifestations of COVID-19, predisposes to arterial and venous thromboembolic disease. The coagulation system can be activated by various viruses, including SARS-CoV-2. Vascular endothelial damage, added to the development of disseminated intravascular coagulation, affects the prognosis and mortality from this disease. Treatment is aimed at the prevention, early detection and timely interventions of all coagulation disorders generated by COVID-19. The recommended anticoagulant is low molecular weight heparin, taking into account creatinine clearance, and if major invasive procedures will be performed, unfractionated heparin is a safe option.

Palabras llave : Intravascular disseminated coagulation; Low molecular weight heparin; Immunothrombosis; Venous thromboembolism.